{
  "context": {
    "rules": [
      "Rule1: Provided that the drug is designated as a breakthrough therapy, if the drug is not profitable, then the clinical trial for the drug is completed.",
      "Rule2: Either there is a manufacturing issue with the drug, or the drug receives fast track approval, or the drug is designated as a breakthrough therapy.",
      "Rule3: Whenever contamination is found in the drug, it is not the case that there is a manufacturing issue with the drug.",
      "Rule4: Either contamination is found in the drug or there is a quality control failure for the drug.",
      "Rule5: Under the condition that there is a quality control failure for the drug, a recall is issued for the drug.",
      "Rule6: Either the drug undergoes market withdrawal, or if a recall is issued for the drug, then it is not the case that there is a manufacturing issue with the drug.",
      "Rule7: Provided that the company makes a financial investment in the drug, the drug is profitable.",
      "Rule8: If the drug receives venture capital funding, then the drug is profitable.",
      "Rule9: Provided that the company conducts an initial public offering, the company makes a financial investment in the drug.",
      "Rule10: Either the company conducts an initial public offering or the drug receives private equity investment.",
      "Rule11: Provided that an application is submitted to the regulatory agency, the application is reviewed by the regulatory agency.",
      "Rule12: Given that the drug has a successful phase 3 trial, if the drug receives private equity investment, then the drug receives venture capital funding.",
      "Rule13: Either the drug has a successful phase 3 trial or the drug receives regulatory approval.",
      "Rule14: If the drug receives regulatory approval, then a marketing campaign is conducted for the drug.",
      "Rule15: Under the condition that the drug receives regulatory approval, the drug receives reimbursement approval.",
      "Rule16: Provided that the drug is launched on the market, if the drug receives private equity investment, then the drug receives venture capital funding.",
      "Rule17: If a marketing campaign is conducted for the drug, then the drug is launched on the market.",
      "Rule18: Either the drug uses blockchain tracking or the drug uses traditional tracking.",
      "Rule19: Provided that the drug uses traditional tracking, the drug is profitable.",
      "Rule20: Whenever the drug is a counterfeit product, the drug faces generic competition.",
      "Rule21: Provided that the drug is a counterfeit product, it is not the case that the drug is an authentic product.",
      "Rule22: Either the drug is a counterfeit product, or if the drug uses blockchain tracking, the drug is profitable.",
      "Rule23: If the drug is distributed illegally, then the drug experiences a supply chain disruption.",
      "Rule24: Under the condition that the drug is distributed illegally, there is a storage violation for the drug.",
      "Rule25: Either the drug is distributed legally or the drug is not distributed illegally.",
      "Rule26: If the drug has a compliance certificate, then either the drug receives full approval or the drug does not receive conditional approval.",
      "Rule27: Either the company undergoes an internal audit or the company undergoes an external audit.",
      "Rule28: Provided that the company undergoes an external audit, the drug has a compliance certificate.",
      "Rule29: Either the company maintains compliance or the company does not commit a regulatory violation.",
      "Rule30: Either the drug undergoes an accelerated review or the drug undergoes a standard review.",
      "Rule31: Given that the drug undergoes a standard review, if the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, it is not the case that the technology for the drug is approved.",
      "Rule32: Provided that clinical trials are required for the drug, if the application is reviewed by the regulatory agency, then given that the drug is not profitable, the technology for the drug is not approved.",
      "Rule33: Either clinical trials are required for the drug or the drug meets safety standards.",
      "Rule34: If the drug has a rare disease indication, then either the drug has orphan drug status, or provided that the drug undergoes an accelerated review, then if the drug meets safety standards, whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "Rule35: Either the drug has a rare disease indication or the drug has a common disease indication.",
      "Rule36: Either the drug is a combination therapy, or if the drug has a common disease indication, then either the drug has orphan drug status, or provided that the drug undergoes an accelerated review, then if the drug meets safety standards, given that the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "Rule37: If the drug has a drug interaction issue, then the drug has adverse events.",
      "Rule38: Whenever the drug undergoes post-market surveillance, the drug undergoes safety monitoring.",
      "Rule39: Either the drug undergoes post-market surveillance or the drug undergoes pre-market testing.",
      "Rule40: Given that the drug undergoes pre-market testing, if the drug has a drug interaction issue, then the drug does not have adverse events.",
      "Rule41: Provided that a health economics study is conducted for the drug, either the drug uses value-based pricing, or if it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control.",
      "Rule42: Either a health economics study is conducted for the drug or outcomes research is conducted for the drug.",
      "Rule43: If outcomes research is conducted for the drug, then either the drug uses value-based pricing, or given that it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, the drug is under price control.",
      "Rule44: Under the condition that a patent is granted for the drug, the drug has patent exclusivity.",
      "Rule45: If the drug has patent exclusivity, then the drug receives a patent extension.",
      "Rule46: Whenever the drug receives a patent extension, if a patent is filed for the drug, then provided that it is not the case that if the drug receives regulatory approval then the drug is launched on the market, the drug has market exclusivity.",
      "Rule47: Given that the drug has patent protection, if the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "Rule48: Under the condition that the drug faces generic competition, it is not the case that a biosimilar version of the drug is available.",
      "Rule49: If there is patent litigation for the drug, then whenever the drug faces generic competition, a biosimilar version of the drug is available.",
      "Rule50: Either there is patent litigation for the drug or there is a patent settlement for the drug.",
      "Rule51: Whenever a manufacturing process uses technology for the drug, the drug is produced through automated production.",
      "Rule52: If a manufacturing process uses technology for the drug, then the drug is produced through manual production.",
      "Rule53: Either a manufacturing process uses technology for the drug or there is no patent infringement for the drug.",
      "Rule54: Under the condition that the drug is produced through manual production, the drug is produced through hybrid production.",
      "Rule55: Provided that the drug is produced through hybrid production, the drug is not produced through automated production.",
      "Rule56: Given that the drug experiences a supply chain disruption, production of the drug is delayed.",
      "Rule57: If the drug has an alternative supplier, then production of the drug is not delayed.",
      "Rule58: Either the drug has an alternative supplier or the drug has a backup manufacturer.",
      "Rule59: Whenever the drug has a backup manufacturer, production of the drug is not delayed.",
      "Rule60: If there is a storage violation for the drug, then the drug has a humidity issue.",
      "Rule61: Either the drug undergoes quality assurance or if the drug has a humidity issue, then the drug experiences a temperature excursion.",
      "Rule62: Either the drug undergoes a stability study, or the drug undergoes batch testing, or the drug does not undergo quality assurance.",
      "Rule63: Provided that the drug receives fast track approval, if the drug is not profitable, then the clinical trial for the drug is completed.",
      "Rule64: Provided that it is not the case that if the drug is a counterfeit product then the drug is an authentic product, the drug is distributed illegally.",
      "Rule65: If it is not the case that if the company undergoes an internal audit then the drug has a compliance certificate, then the company commits a regulatory violation.",
      "Rule66: Provided that it is not the case that if the drug meets safety standards then if the application is reviewed by the regulatory agency then if the drug is not profitable then the technology for the drug is not approved, the drug has a drug interaction issue.",
      "Rule67: Whenever it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, the drug is not under price control.",
      "Rule68: Provided that it is not the case that either the drug is included in a formulary or if the drug receives reimbursement approval then if the drug receives private equity investment then the drug receives venture capital funding, the drug requires prior authorization.",
      "Rule69: If it is not the case that either the drug is included in a formulary or if the drug receives reimbursement approval then if the drug receives private equity investment then the drug receives venture capital funding, then the drug does not require prior authorization.",
      "Rule70: Given that it is not the case that if there is a patent settlement for the drug then if the drug faces generic competition then a biosimilar version of the drug is available, there is patent infringement for the drug.",
      "Rule71: Provided that it is not the case that if it is not the case that if the drug undergoes safety monitoring then if the drug has a drug interaction issue then the drug does not have adverse events then the drug has a risk management plan, the drug has a black box warning.",
      "Rule72: If it is not the case that if the drug is not profitable then the technology for the drug is not approved, then the drug receives conditional approval.",
      "Rule73: Whenever the drug does not have patent protection, a generic version of the drug is available.",
      "Rule74: Provided that the drug does not have patent protection, it is not the case that a generic version of the drug is available.",
      "Rule75: If the drug is not profitable, then the technology for the drug is approved.",
      "Rule76: If the drug is not profitable, then the clinical trial for the drug is not completed."
    ],
    "facts": [
      "Fact1: An application is submitted to the regulatory agency.",
      "Fact2: A patent is filed for the drug.",
      "Fact3: A patent is granted for the drug.",
      "Fact4: It is not the case that the drug undergoes market withdrawal.",
      "Fact5: It is not the case that the drug is distributed legally.",
      "Fact6: It is not the case that the drug receives full approval.",
      "Fact7: It is not the case that the company maintains compliance.",
      "Fact8: It is not the case that the drug has orphan drug status.",
      "Fact9: It is not the case that the drug is a combination therapy.",
      "Fact10: It is not the case that the drug has a risk management plan.",
      "Fact11: It is not the case that the drug has a black box warning.",
      "Fact12: It is not the case that the drug has a patient assistance program.",
      "Fact13: It is not the case that the drug uses value-based pricing.",
      "Fact14: It is not the case that the drug has market exclusivity.",
      "Fact15: It is not the case that the drug is included in a formulary.",
      "Fact16: It is not the case that the drug experiences a temperature excursion.",
      "Fact17: It is not the case that the drug undergoes batch testing.",
      "Fact18: It is not the case that the drug undergoes a stability study."
    ]
  },
  "question": "The drug is profitable."
}